

OSIMERTINIB

full description

INDICATIONS:

Locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) following progression on a 1st line EGFR tyrosine kinase inhibitor (TA653)

Untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (TA654).

Adjuvant treatment after complete tumour resection in adults with stage 1b to 3a NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, only if osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity. (TA10756)

DOSING:

Osimertinib PO 80mg od continuously
28 day cycle

regimen name	OSIMERTINIB
diagnosis	EGFR+ve & PDL1+ve NSCLC NOS, EGFR+ve Adeno NSCLC, EGFR+ve NSCLC NOS, EGRF+ve & PDL1+ve Adeno NSCLC, NSCLC with EGFR mutation(s)
version number	4.01

version no	amended date	amended by	summary
1	Tue Feb 09 2016 11:19:58 GMT+0000 (Greenwich Mean Time)	GAIL POVEY	
2	Wed Jan 12 2022 13:03:46 GMT+0000 (Greenwich Mean Time)	Euan Pratt	Pharmacy instructions changed to supply original pack
3	Thu Jan 13 2022 12:30:59 GMT+0000 (Greenwich Mean Time)	Gail Povey	Random glucose test added
4	Fri Aug 16 2024 11:11:14 GMT+0100 (British Summer Time)	Jason Hughes	Change critical test expiries
4.01	Tue Sep 03 2024 12:49:13 GMT+0100 (British Summer Time)	Gail Povey	Replaced dose reduction guidance with hyperlink to COIN document.

Treatment day: 1 day type: O slots: 2

drug name	route	vehicle	dose	dose calc	infus. time	frequency	duration	start time	line	fluid vol..	fluid calc
critical test:	HB100 14D, HAEMOGLOBIN>100 14D, range: 100-> 172										
critical test:	PLT100 14D, PLATELETS>100 14D, range: 100-> 600										
critical test:	WBC2 14D, WBC>2 14 DAYS , range: 2-> 11										
critical test:	NEUT1.5 14, NEUTROPHILS >1.5 14DAY , range: 1.5-> 7.5										
critical test:	CREAT 14D, CREATININE 14D, range: 40-> 135										
critical test:	BILI 14D, BILIRUBIN 14D, range: 0-> 21										
critical test:	RBG 14D, Random blood glucose 14 days , range: 3-> 12										
OSIMERTINIB	Oral	None	80 mg	FLAT		od	28 days			0	
note:	The tablet should be swallowed whole with water and it should not be crushed, split or chewed. PHARMACY: dispense original pack(s).										

Treatment day: 28 day type: X slots: 0

drug name	route	vehicle	dose	dose calc	infus. time	frequency	duration	start time	line	fluid vol..	fluid calc
review											

CLINICAL DETAILS

Please check the latest version of the Summary of Product Characteristics for the most up-to-date information on dose reductions, warnings and side effects.

For renal and hepatic dose reductions please check link to COIN in the clinical decision support tab above.

ADD NOTE="HbA1C must be checked at the start of treatment but if a result is not available for the first cycle go ahead with treatment and ensure a result obtained before the next cycle. Blood glucose should be checked at each cycle unless otherwise stated by prescriber. If the result is >12mmol/L refer to Glycaemia protocol. "

<https://nhswales365.sharepoint.com/sites/SBUClinicalPathways/COIN/Forms/AllItems.aspx?id=%2Fsites%2FSBUClinicalPathways%2FCOIN%2FCLINICAL%20SPECIALTIES%2Foncology%2FChemocare%20Information%2FCID4892%20Dose%20Reco>

Regimen Entry

Pharmacist - PSU

Date

Regimen

Pharmacist - QA

Date

Regimen Verified

Consultant

Date

Medical Director

Date